Rome, Italy
Rome, Italy

Time filter

Source Type

News Article | May 2, 2017
Site: www.cnet.com

Theranos has settled a pair of lawsuits filed by an investor that claimed the embattled blood-testing company misled it to attract a nearly $100 million investment. The settlement announced Monday resolves a lawsuit filed by hedge fund Partner Fund Management in October that accused Theranos of engaging in securities fraud through a "series of lies" to secure a $96 million investment. Another filing in April by PFM accused Theranos of misleading directors by using a shell company to "secretly" buy commercial lab equipment and faking blood tests in presentations with prospective investors and business partners. Terms of the settlement will remain confidential, Theranos said in a statement. "Theranos is pleased to have resolved both lawsuits with PFM," Theranos general counsel David Taylor said in a news release. "Although we are confident that we would have prevailed at trial, resolution of these two cases allows our tender offer to go forward and enables us to return our focus where it belongs, which is on executing our business plans and delivering value for our shareholders." It's the latest twist in a downward spiral of a once-promising company that set out to innovate blood testing. Two years ago, it was valued at $9 billion. But it has faced increased scrutiny, along with civil and criminal investigations, since a Wall Street Journal report in October 2015 suggested Theranos' blood-testing devices were flawed. In July, the CMMS revoked the company's Clinical Laboratory Improvement Amendments certificate, an action that prohibits Theranos CEO Elizabeth Holmes from operating a lab for two years. A week before PFM filed its lawsuit in October, Holmes announced plans to shut down all its clinical labs and Theranos Wellness Centers, closures that will result in 340 employees being laid off. Virtual reality 101: CNET tells you everything you need to know about VR.


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Medical Laboratory Testing Services 2017 to 2022 - Europe Version" report to their offering. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenomics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Medical Laboratory Testing Services - 2016 to 2019 Europe Version" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. The report includes detailed breakouts for 15 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report. 6. The Future of the Clinical Laboratory For more information about this report visit http://www.researchandmarkets.com/research/d4r96x/medical


News Article | April 27, 2017
Site: globenewswire.com

DUBLIN, Ireland, April 27, 2017 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2017. Total revenues for Q1, 2017 were $23.5m which was marginally higher than that recorded in Q1, 2016. Point-of-Care revenues for Q1, 2017 increased by $0.7m compared to Q1, 2016. This was attributable to higher HIV sales in Africa.  This is reflective of the fluctuating nature of this market particularly in the context of Q1, 2016 revenues being unusually low. Meanwhile, Clinical Laboratory revenues decreased from $20.2m to $19.5m, a decrease of 3.6% compared to Q1, 2016.  This decrease was attributable to the impact of culling a range of older declining product at the end of 2016. Gross margin for the quarter was 42%. This was a decrease when compared to the gross margin reported in Q1, 2016 of 43.1% though higher than the 40% reported in Q4, 2016. This decrease was partly due to lower production levels in the immediate aftermath of our recent product cull. Research and Development expenses increased from $1.1m to $1.3m. Meanwhile Selling, General and Administrative (SG&A) remained constant at $7.0m. Operating profit for the quarter decreased from $1.8m to $1.3m – due to the combined impact of the lower gross margin and slightly higher indirect costs. Financing income for the quarter was marginally lower at $0.2m reflecting lower deposit levels and interest rates. Meanwhile, interest payable, mainly arising on the Company’s exchangeable notes, was static at $1.2m.  Further non-cash income of $1m was recognised in the quarter.  This was due to a gain of $1.2m arising on a decrease in the fair value of the embedded derivatives associated with the exchangeable notes and was partly offset by non-cash interest of $0.2m. The Company recorded a profit of $1.2m for the quarter which equated to earnings per share of 5.6 cents.  However, excluding non-cash items the profit for the quarter was $0.2m or an EPS of 1.0 cents. Fully diluted EPS for the quarter was 5.0 cents compared to 6.4 cents in Q1, 2016. EBITDA before share option expense for the quarter was $2.7m. During the quarter, the Company repurchased 181,000 ADRs at an average price of $6.40 and with a total value of $1.2m. A further 134,000 ADRs at an average price of $5.63 have been repurchased since quarter end. This brings the total purchased since the beginning of the program to over 1.4m shares with a total value of $11.9m. Commenting on the results, Kevin Tansley, Chief Financial Officer, said “Our operating profit of $1.3m this quarter was lower than the $1.8m recorded in the equivalent quarter last year due to slightly lower gross margins and marginally higher indirect costs.  However, it represents a significant increase on Q4, 2016’s operating profit of $0.6m.  Margins have started to rebound towards more normal levels and this will continue with revenue growth in the future, whilst indirect costs are being kept under control.” Ronan O’Caoimh, CEO of Trinity said “We were pleased to see an improvement in profitability from the last quarter of 2016, particularly as we are now seeing the impact of culling some of our older products at the end of last year. Quarter 1 typically represents our lowest revenue quarter and we believe that future profitability growth can be achieved by concentrating on growing our key business lines with a particular emphasis on Diabetes, Autoimmunity and HIV.  At the same time we will continue our share buyback program which is now approaching $12m since being initiated in 2016.” Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission. Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com. * Under IAS 33 Earnings per Share, diluted earnings per share cannot be anti-dilutive. Therefore, diluted earnings per ADR in quarter 1, 2016 in accordance with IFRS would be a loss of 5.8 cents (i.e. equal to basic earnings per ADR). ** Excluding once-off charges The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company’s accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting). The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company’s accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting). The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company’s accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).


News Article | April 27, 2017
Site: globenewswire.com

DUBLIN, Ireland, April 27, 2017 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2017. Total revenues for Q1, 2017 were $23.5m which was marginally higher than that recorded in Q1, 2016. Point-of-Care revenues for Q1, 2017 increased by $0.7m compared to Q1, 2016. This was attributable to higher HIV sales in Africa.  This is reflective of the fluctuating nature of this market particularly in the context of Q1, 2016 revenues being unusually low. Meanwhile, Clinical Laboratory revenues decreased from $20.2m to $19.5m, a decrease of 3.6% compared to Q1, 2016.  This decrease was attributable to the impact of culling a range of older declining product at the end of 2016. Gross margin for the quarter was 42%. This was a decrease when compared to the gross margin reported in Q1, 2016 of 43.1% though higher than the 40% reported in Q4, 2016. This decrease was partly due to lower production levels in the immediate aftermath of our recent product cull. Research and Development expenses increased from $1.1m to $1.3m. Meanwhile Selling, General and Administrative (SG&A) remained constant at $7.0m. Operating profit for the quarter decreased from $1.8m to $1.3m – due to the combined impact of the lower gross margin and slightly higher indirect costs. Financing income for the quarter was marginally lower at $0.2m reflecting lower deposit levels and interest rates. Meanwhile, interest payable, mainly arising on the Company’s exchangeable notes, was static at $1.2m.  Further non-cash income of $1m was recognised in the quarter.  This was due to a gain of $1.2m arising on a decrease in the fair value of the embedded derivatives associated with the exchangeable notes and was partly offset by non-cash interest of $0.2m. The Company recorded a profit of $1.2m for the quarter which equated to earnings per share of 5.6 cents.  However, excluding non-cash items the profit for the quarter was $0.2m or an EPS of 1.0 cents. Fully diluted EPS for the quarter was 5.0 cents compared to 6.4 cents in Q1, 2016. EBITDA before share option expense for the quarter was $2.7m. During the quarter, the Company repurchased 181,000 ADRs at an average price of $6.40 and with a total value of $1.2m. A further 134,000 ADRs at an average price of $5.63 have been repurchased since quarter end. This brings the total purchased since the beginning of the program to over 1.4m shares with a total value of $11.9m. Commenting on the results, Kevin Tansley, Chief Financial Officer, said “Our operating profit of $1.3m this quarter was lower than the $1.8m recorded in the equivalent quarter last year due to slightly lower gross margins and marginally higher indirect costs.  However, it represents a significant increase on Q4, 2016’s operating profit of $0.6m.  Margins have started to rebound towards more normal levels and this will continue with revenue growth in the future, whilst indirect costs are being kept under control.” Ronan O’Caoimh, CEO of Trinity said “We were pleased to see an improvement in profitability from the last quarter of 2016, particularly as we are now seeing the impact of culling some of our older products at the end of last year. Quarter 1 typically represents our lowest revenue quarter and we believe that future profitability growth can be achieved by concentrating on growing our key business lines with a particular emphasis on Diabetes, Autoimmunity and HIV.  At the same time we will continue our share buyback program which is now approaching $12m since being initiated in 2016.” Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission. Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com. * Under IAS 33 Earnings per Share, diluted earnings per share cannot be anti-dilutive. Therefore, diluted earnings per ADR in quarter 1, 2016 in accordance with IFRS would be a loss of 5.8 cents (i.e. equal to basic earnings per ADR). ** Excluding once-off charges The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company’s accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting). The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company’s accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting). The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company’s accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).


News Article | April 27, 2017
Site: globenewswire.com

DUBLIN, Ireland, April 27, 2017 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2017. Total revenues for Q1, 2017 were $23.5m which was marginally higher than that recorded in Q1, 2016. Point-of-Care revenues for Q1, 2017 increased by $0.7m compared to Q1, 2016. This was attributable to higher HIV sales in Africa.  This is reflective of the fluctuating nature of this market particularly in the context of Q1, 2016 revenues being unusually low. Meanwhile, Clinical Laboratory revenues decreased from $20.2m to $19.5m, a decrease of 3.6% compared to Q1, 2016.  This decrease was attributable to the impact of culling a range of older declining product at the end of 2016. Gross margin for the quarter was 42%. This was a decrease when compared to the gross margin reported in Q1, 2016 of 43.1% though higher than the 40% reported in Q4, 2016. This decrease was partly due to lower production levels in the immediate aftermath of our recent product cull. Research and Development expenses increased from $1.1m to $1.3m. Meanwhile Selling, General and Administrative (SG&A) remained constant at $7.0m. Operating profit for the quarter decreased from $1.8m to $1.3m – due to the combined impact of the lower gross margin and slightly higher indirect costs. Financing income for the quarter was marginally lower at $0.2m reflecting lower deposit levels and interest rates. Meanwhile, interest payable, mainly arising on the Company’s exchangeable notes, was static at $1.2m.  Further non-cash income of $1m was recognised in the quarter.  This was due to a gain of $1.2m arising on a decrease in the fair value of the embedded derivatives associated with the exchangeable notes and was partly offset by non-cash interest of $0.2m. The Company recorded a profit of $1.2m for the quarter which equated to earnings per share of 5.6 cents.  However, excluding non-cash items the profit for the quarter was $0.2m or an EPS of 1.0 cents. Fully diluted EPS for the quarter was 5.0 cents compared to 6.4 cents in Q1, 2016. EBITDA before share option expense for the quarter was $2.7m. During the quarter, the Company repurchased 181,000 ADRs at an average price of $6.40 and with a total value of $1.2m. A further 134,000 ADRs at an average price of $5.63 have been repurchased since quarter end. This brings the total purchased since the beginning of the program to over 1.4m shares with a total value of $11.9m. Commenting on the results, Kevin Tansley, Chief Financial Officer, said “Our operating profit of $1.3m this quarter was lower than the $1.8m recorded in the equivalent quarter last year due to slightly lower gross margins and marginally higher indirect costs.  However, it represents a significant increase on Q4, 2016’s operating profit of $0.6m.  Margins have started to rebound towards more normal levels and this will continue with revenue growth in the future, whilst indirect costs are being kept under control.” Ronan O’Caoimh, CEO of Trinity said “We were pleased to see an improvement in profitability from the last quarter of 2016, particularly as we are now seeing the impact of culling some of our older products at the end of last year. Quarter 1 typically represents our lowest revenue quarter and we believe that future profitability growth can be achieved by concentrating on growing our key business lines with a particular emphasis on Diabetes, Autoimmunity and HIV.  At the same time we will continue our share buyback program which is now approaching $12m since being initiated in 2016.” Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission. Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com. * Under IAS 33 Earnings per Share, diluted earnings per share cannot be anti-dilutive. Therefore, diluted earnings per ADR in quarter 1, 2016 in accordance with IFRS would be a loss of 5.8 cents (i.e. equal to basic earnings per ADR). ** Excluding once-off charges The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company’s accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting). The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company’s accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting). The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company’s accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).


News Article | April 18, 2017
Site: www.businesswire.com

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics Corporation (Ambry) is calling on psychiatrists, psychologists and behavioral specialists to encourage their patients with autism, along with their family members, to sign up for a new study conducted through Ambry’s data sharing program, AmbryShare. With this program, Ambry is taking a step towards discovering possible associations between genes and autism, so clinicians can provide their patients with targeted treatments and therapies much earlier in life. “What’s unique about AmbryShare’s approach is that we collect genetic information from clinics and families from all over the world to answer questions that can’t be answered with just a handful of patients,” said Brigette Tippin Davis, PhD, Ambry’s Director of Emerging Genetic Medicine. “The great thing about Ambry partnerships is that we are building connections between research institutions and empowering them to develop new approaches to treating patients with autism based on genetic profiles.” So far, dozens of behavioral clinics and other medical offices have contributed to AmbryShare studies by encouraging participation from their patients. Ambry strives to enroll more than 10,000 patients from clinics nationally and internationally. “Genetic testing would allow us to personalize treatment from a genetic profile and optimize it together with our rich behavioral data,” said Dennis Dixon, PhD, Chief Strategy Officer at Center for Autism and Related Disorders (CARD). “I really value working with Ambry, knowing this data will have an impact on treatment for our patients and then will still be available for other researchers to access to answer additional research questions. As we each put more samples in, it increases the overall likelihood that we’re going to find something that really makes a difference.” One in 64 children in the United States is diagnosed with an autism spectrum disorder (ASD), which can impact social interaction, communication and behavior. Genetic testing can help identify an underlying cause in up to 40% of autism spectrum disorders. Some genetic causes include chromosome microdeletions/microduplications, fragile X syndrome, Angelman syndrome, and tuberous sclerosis. New gene discovery can allow clinicians to determine their patient’s course of treatment and the gene-disease relationship associated with their individual case of autism. Through the recruitment of a massive cohort, more data will be collected to discover more genes, develop medical management plans and enact preventive strategies. “The scientists need the data to be out there,” said Charles Dunlop, Ambry’s President and Chairman. “We need to know what these diseases are actually doing, what causes them, what gene mutations are associated with them so we can move forward as an industry and move onto the next phase where there is no disease of any kind. A phase where pharmaceutical researchers know exactly what to do, or exactly what problems they’re trying to solve at a minutiae level—that’s when the cures come.” In 2016, Mayo Clinic and University of Utah collaborated with Ambry on a new research study of more than 60,000 patients to help refine breast cancer risk estimates from predisposition genes that are either previously lacking data or have limited data. The study, “Breast cancer risks associated with mutations in cancer predisposition genes identified by clinical genetic testing of 60,000 breast cancer patients” represented the largest genetic study of women with hereditary breast cancer. The large amount of data was able to provide researchers with new information about genes that contributed to breast cancer risk. Ambry wants to provide researchers with the same capabilities for autism. Since 2001, Ambry has been dedicated to scientific research to help empower the scientific community and refine clinician management guidelines so patients may receive tailored medical management. AmbryShare’s initial launch in 2016 provided scientific researchers and clinicians with the largest open, de-identified database of hereditary breast and ovarian cancer cohorts with the goal of achieving a greater understanding of human disease. For more information and to enroll in the AmbryShare autism study, visit the AmbryShare portal here. Ambry Genetics is both College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified. Ambry leads in clinical genetic diagnostics and genetics software solutions, combining both to offer the most comprehensive testing menu in the industry. Ambry has established a reputation for sharing data while safeguarding patient privacy, unparalleled service, and responsibly applying new technologies to the clinical molecular diagnostics market. For more information about Ambry Genetics, visit www.ambrygen.com. About the Center for Autism and Related Disorders (CARD) CARD treats individuals of all ages who are diagnosed with autism spectrum disorder (ASD) at treatment centers around the globe. CARD was founded in 1990 by leading autism expert and clinical psychologist Doreen Granpeesheh, PhD, BCBA-D. CARD treats individuals with ASD using the principles of applied behavior analysis (ABA), which is empirically proven to be the most effective method for treating individuals with ASD and recommended by the American Academy of Pediatrics and the US Surgeon General. CARD employs a dedicated team of over 3,000 individuals across the nation and internationally. For more information, visit www.centerforautism.com or call (855) 345-2273.


News Article | April 26, 2017
Site: www.businesswire.com

DELRAY BEACH, Fla.--(BUSINESS WIRE)--Progeny Genetics LLC (Progeny), a leading risk modeling pedigree software for clinicians, announced today that Jamie L’Heureux, MS, CGC has been appointed to the role of Chief Executive Officer. For 20 years, Progeny has assisted healthcare providers with patient screening, risk analysis, order processing, clinical review, and letter generation. Ms. L’Heureux brings over 12 years of experience in both research and clinical genetics as a Board Certified genetic counselor. She received her Master’s degree in Medical Genetics from the University of Cincinnati’s Genetic Counseling Training Program and began her career at the University of Iowa as a Research Coordinator for several international research projects. Ms. L’Heureux’s strong background in software development includes implementing new laboratory information management systems and designing patient-facing Family History Questionnaires. For the past three years, Ms. L’Heureux served as Software Product Manager at Progeny, and was integral to development of Progeny’s letter generation feature and integrated risk models. “I am excited to be able to use my past experience as a Progeny user, both in the research and clinical genetic counseling settings, to help build upon the strong foundation that Progeny already has established, and make it even more user-friendly for our healthcare provider customers and their patients,” said Ms. L’Heureux. “We have some exciting improvements coming up that are focused on saving clinicians’ time and simplifying their workflow.” As a prominent member of the Progeny leadership team, Ms. L’Heureux helps guide the future of the company by leveraging her extensive experience as a genetic counselor. In addition, her software development knowledge provides a solid foundation for Ms. L’Heureux to harness the needs of Progeny’s healthcare provider clientele. Progeny’s software is available in over 2,400 unique sites in 80 countries worldwide. Progeny has played a prominent role in advancing science by bringing family history to the forefront of genetic healthcare, with the intention that the information provided to healthcare providers will assist them with early detection and intervention to patients with genetic predispositions. Progeny became a subsidiary of Ambry Genetics (Ambry), a genetic testing company based in Aliso Viejo, California, in April 2015. Progeny’s software helps healthcare providers analyze hereditary family history data so clinicians can effectively identify genetic risk factors in patients and their families. For more information about Progeny’s services and support, visit here. Progeny is a subsidiary of Ambry Genetics, providing customizable family history, pedigree, sample, and genetic data management software solutions to healthcare providers worldwide. Using Progeny’s sophisticated technology, healthcare providers can collect family history from patients, review and edit pedigrees, run integrated risk models, order and review genetic testing, and integrate into the electronic medical record, allowing healthcare providers to embrace personalized healthcare like never before. For more information about Progeny, visit www.progenygenetics.com. Ambry Genetics is both College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified. Ambry leads in clinical genetic diagnostics and genetics software solutions, combining both to offer the most comprehensive testing menu in the industry. Ambry has established a reputation for sharing data while safeguarding patient privacy, unparalleled service, and responsibly applying new technologies to the clinical molecular diagnostics market. For more information about Ambry Genetics, visit www.ambrygen.com.


Collaboration will allow OCB's suite of precision oncology In Vitro Diagnostic tests to be rolled out across the People's Republic of China OXFORD, England, April 18, 2017 /PRNewswire/ -- Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced a strategic collaboration with  My-BioMed Biotechnology Ltd. based in Ningbo, Zhejiang, China. Oxford Cancer Biomarkers announces strategic collaboration with My-BioMed Biotechnology Ltd. The partnership includes a licencing deal that will allow My-BioMed Biotechnology Ltd. to access OCB's ColoTox, ColoProg and ColoPredict technologies and to drive uptake across the PRC via a purpose built biomedical laboratory in Ningbo Meishan FTZ. OCB has developed a suite of diagnostic tests for colorectal cancer (CRC) to personalise current treatment pathways and plans to develop similar tests for other cancer indications. As of 2015, 274,000 new cases of colorectal cancer are diagnosed every year in the People's Republic of China, 190,400 of these cases prove fatal. My-BioMed (MBM) is a leading precision medicine organisation which focused on bringing global innovation to the Chinese market. The team at MBM has extensive experience in product development and launch including clinical development, regulatory strategy, clinical laboratory services, sales and marketing. MBM's core business model is driven by patient and clinician needs. Jackson Zhu, CEO of MBM, commented "We are very happy to launch the first three proprietary CRC diagnostic tests discovered at Oxford University and developed by OCB, aimed at specifically benefitting patients in China. Both MBM and OCB have solidified through this partnership, a long-term commitment to China, with the aim of developing and launching a suite of unique diagnostic products." Prof David Kerr, Chief Medical Officer of OCB, commented "Our strategic partnership with MBM will allow patients across China to access OCB's suite of precision oncology diagnostic technologies. We are looking forward to working closely with MBM to tailor our offerings to the specific needs of the Chinese market and building a robust product pipeline of diagnostics specifically aimed at the Chinese population. This is an important step in our mission to drive global access to technologies that allow patient stratification and individually tailored treatment pathways." About Oxford Cancer Biomarkers Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient.  Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division in Oxford University. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University. Investors in OCB include Longwall Venture Partners LLP, Esperante BV and the University. For more information, please visit: http://www.oxfordcancerbiomarkers.com Contact detailsOxford Cancer Biomarkers Ltd           Tel:  +44 1865 784743Prof.Nick La Thangue, CEO / David Oxlade, Chairman About Ningbo My-BioMed Biotechnology Co.,Ltd.  In pursuit of its vision of "Bridging World Innovation in Precision Medicine", My-BioMed (MBM) is dedicated to providing personalized solutions to clinicians and patients, and to building an integrated commercialization platform for innovation. Supported by Ningbo Meishan's Healthcare industry development strategy, MBM, established in May 2016, has attracted a group of talented individuals with experience across a range of disciplines including business development, market access, clinical development, registration, clinical lab services, sales and marketing. Located at Ningbo Meishan Free Trade Port, My-BioMed Clinical Laboratory, MBM wholly owned subsidiary, has been granted pre-approval from the Health and Family Plan Commission, and will be certified within this year. Ningbo My-BioMed Biotechnology Co.,Ltd.    E-Mail:info@my-biomed.com  CEO:  Jackson Zhu Photo - http://photos.prnasia.com/prnh/20170414/1826123-1


News Article | April 17, 2017
Site: www.prweb.com

Visiun is pleased to announce the formation of a new Advisory Board, bringing together experts in the laboratory industry to provide input and perspective to the fast-changing environment of the hospital laboratory and Visiun’s leading laboratory analytics tool, Performance Insight™. The first member of the newly formed panel is Denise Uettwiller-Geiger, Ph.D., DLM(ASCP), award-winning Clinical Chemist, Director of Clinical Trials at John T Mather Hospital, and author of more than 80 clinical journal articles. Dr. Uettwiller-Geiger works in a laboratory that processes more than 2.4 million tests per year, assists with new technology and menu expansion, and serves as principal investigator for clinical trials in the areas of infectious disease, cardiac, point of care, and other new technologies. She also provides expert education, guidance and consultation to clinicians. As the first member of Visiun’s Advisory Board, Dr. Uettwiller-Geiger will use her expertise to provide strategic advice and recommendations to the expansion of Performance Insight and how it can best support laboratory management in improving operational performance most effectively. “Visiun is pleased to welcome Dr. Uettwiller-Geiger as the first member of our new Advisory Panel,” says Tom Joseph, Visiun President and CEO. “We look forward to working with Dr. Uettwiller-Geiger and receiving thoughtful guidance and recommendations from an industry leader like herself so we can best serve the laboratory community.” Dr. Uettwiller-Geiger received her Master of Health Sciences and an Advanced Certificate in Health Care Management, from the W. Averall Harriman School for Policy and Management, from Stony Brook University, Stony Brook, New York, and a PhD in Biomedical Science from Pacific Western University, Brentwood, California. In 2010, she received the American Association of Clinical Chemistry (AACC) Management Sciences Abstract Award for Outstanding Project; the National Academy of Clinical Biochemistry (NACB) Distinguished Abstract Award; and the Brookhaven’s Women’s Recognition Award for Science. In 2011, she received the Best Lab Practice Award from American Society of Clinical Pathology (ASCP) and the Siemens 2011 Inspired Healthcare Outcomes Award for her work in reducing MRSA infection rates. In 2015, she received the ICE Award (Increasing Clinical Effectiveness) from the Clinical Laboratory Management Association for her work in reducing hospital acquired infections. Spencer, M., Uettwiller-Geiger, D., Sanguinet, J., Johnson, H. B., & Graham, D. (2016). Infection preventionists and laboratorians: Case studies on successful collaboration. American Journal of Infection Control, 44(9), 964-968. Christenson, R. H., Jacobs, E., Uettwiller-Geiger, D., Estey, M. P., Lewandrowski, K., Koshy, T., Kupfer, K., Li, Y., & Wesenber, J. (2017). Comparison of 13 Commercially Available Cardiac Troponin Assays in a Multicenter North American Study. The Journal of Applied Laboratory Medicine, 1(5), 544-561. Visiun, Inc. is the leading provider of performance analytics to the laboratory industry. Headquartered in Ann Arbor, Michigan, Visiun has been providing services to the laboratory industry for over six years, with hundreds of laboratories installed across the United States. Performance Insight™, Visiun's core product, provides laboratory managers with a comprehensive suite of analytics that deliver immediate improvements in performance, efficiency, and quality. For more information, please visit http://www.visiun.com.


News Article | May 4, 2017
Site: www.businesswire.com

LONDON--(BUSINESS WIRE)--Technavio analysts forecast the global point-of-care (POC) lipid testing market to grow at a CAGR of more than 6% during the forecast period, according to their latest report. The research study covers the present scenario and growth prospects of the global POC lipid testing market for 2017-2021. To calculate the market size, Technavio analysts consider the generated from sales/volume/value of POC lipid testing products. The global POC lipid testing market is driven by numerous factors such as the increasing rate of unhealthy lifestyles, which increases the prevalence of NCDs, especially CVDs. Other key factors such as high consumption of alcohol, hypertension, smoking, diabetes, and broader patient accessibility to advanced treatments that deliver faster results drive the growth of the global POC lipid testing market. Want more information on this market? View a market snapshot before purchasing the report Technavio reports answer key questions relating to market size and growth, drivers and trends, top vendors, challenges, and more. Technavio also offers customization on reports based on specific client requirement. Technavio healthcare and life sciences analysts highlight the following three factors that are contributing to the growth of the global POC lipid testing market: An organized reimbursement structure in low and middle-income countries is an effective measure to reduce the healthcare out-of-pocket expenditure of individuals. There has been a continuous effort taken by governments to reduce the length of hospital stay and curb the healthcare expenditure. The average length of stay (ALOS) in hospitals is often seen as an indicator of efficiency. Srinivas Sashidhar, a lead in-vitro diagnostics research analyst at Technavio, says, “The availability of reimbursement policies for POC lipid profile testing is another driver that drives the market growth. Reimbursements for POC lipid testing can be obtained through the accreditation of the Clinical Laboratory Improvement Amendments.” The rise in unhealthy lifestyle and growing number of CVDs around the world drive the market for POC lipid testing. According to the CDC, 73.5 million adults (31.7%) in the US have high LDL, which is the main cause of high cholesterol in the blood. Such individuals are approximately twice at the risk of heart disease as people with normal levels. “The prevalence of CVDs such as myocardial infarction, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, and others is also a major cause for the growth of the global POC lipid testing market,” adds Srinivas. POC lipid screening of asymptomatic or carrier adults at wellness events such as corporate workplaces, pharmacies, and schools offers several advantages over conventional laboratory testing. Here, they can access their results immediately without any hindrance. According to PTS Diagnostics, the advantage of POC lipid testing over conventional laboratory testing is that it requires less than 5 minutes to perform and cholesterol and triglycerides tests can be carried out during consultation for the screening and diagnosis of hypercholesterolemia and CVDs. Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like oncology, vaccines, and urology devices. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently. Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies. Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users. If you are interested in more information, please contact our media team at media@technavio.com.

Loading Clinical Laboratory collaborators
Loading Clinical Laboratory collaborators